PRTA insider trading
NasdaqGS HealthcarePROTHENA CORP PUBLIC LTD CO — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PROTHENA CORP PUBLIC LTD CO
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Company website: www.prothena.com
PRTA insider activity at a glance
FilingIQ has scored 657 insider transactions for PRTA since Mar 20, 2015. The most recent filing in our index is dated Apr 10, 2026.
Across the full history, 17 open-market purchases
and 362 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PRTA insider trades is 59.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
13F funds holding PRTA
Frequently asked
- How many insider trades does FilingIQ track for PRTA?
- FilingIQ tracks 657 Form 4 insider transactions for PRTA (PROTHENA CORP PUBLIC LTD CO), covering filings from Mar 20, 2015 onwards. 8 of those were filed in the last 90 days.
- Are PRTA insiders net buyers or net sellers?
- Across the full Form 4 history for PRTA, 17 transactions (3%) were open-market purchases and 362 (55%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PRTA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PRTA in?
- PROTHENA CORP PUBLIC LTD CO (PRTA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $482.31M.
Methodology & sources
Every PRTA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.